A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
Launched by PHARMACIA AND UPJOHN · Aug 30, 2001
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are HIV-positive.
- • Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.
- • Have a CD4 cell count of at least 50 cells/mm3.
- • Are at least 14 years old (consent of parent or guardian is required if under 18).
- • Exclusion Criteria
- You will not be eligible for this study if you:
- • Have ever taken an anti-HIV drug other than ZDV.
- • Have taken ZDV for more than 1 month.
About Pharmacia And Upjohn
Pharmacia and Upjohn, a global biopharmaceutical company, specializes in the research, development, and commercialization of innovative therapies that address unmet medical needs across multiple therapeutic areas. With a strong commitment to advancing healthcare, the company leverages cutting-edge science and technology to improve patient outcomes. Pharmacia and Upjohn is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring the safety and efficacy of its products while fostering collaboration with healthcare professionals and regulatory authorities worldwide. Through its comprehensive portfolio, the company aims to enhance the quality of life for patients and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Annandale, Virginia, United States
New York, New York, United States
Los Angeles, California, United States
Pittsburgh, Pennsylvania, United States
San Francisco, California, United States
Memphis, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials